Consumer medicine information

Glaumox 500 mg Powder for Injection

Acetazolamide

BRAND INFORMATION

Brand name

Glaumox Powder for Injection

Active ingredient

Acetazolamide

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Glaumox 500 mg Powder for Injection.

1. Why am I being given Glaumox?


Glaumox contains the active ingredient acetazolamide. Glaumox is used to lower raised pressure in the eye and to treat glaucoma. It is also used to treat some other conditions such as epilepsy and fluid build up due to heart failure or medicines. For more information, see Section 1. Why am I being given Glaumox? in the full CMI.

2. What should I know before I am given Glaumox?


Do not use if you have ever had an allergic reaction to any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.
For more information, see Section 2. What should I know before I am given Glaumox? in the full CMI.

3. What if I am taking other medicines?


Some medicines may interfere with Glaumox and affect how it works.
A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How is Glaumox given?

  • Glaumox Powder for Injection will be injected by your doctor into a vein.
  • More instructions can be found in Section 4. How is Glaumox given? in the full CMI.

5. What should I know while being given Glaumox?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using Glaumox.
Things you should not do
  • If you are pregnant or breastfeeding do not use Glaumox unless your doctor says so.
  • Glaumox should not be given for long term use in patients with chronic noncongestive angle-closure glaucoma.
  • If you are allergic to sulfur medicines, you may be allergic to Glaumox.
Driving or using machines
  • Be careful driving or operating machinery after you have been given Glaumox. Glaumox may cause dizziness in some people.
Drinking alcohol
  • Tell your doctor if you drink alcohol. Alcohol may increase the side effects of some medicines.
Looking after your medicine
  • Glaumox is kept in the pharmacy or ward of a hospital in a cold dry place, where the temperature stays below 25°C.

For more information, see Section 5. What should I know while being given Glaumox? in the full CMI.

6. Are there any side effects?


Glaumox may cause short sightedness, headache, nausea, vomiting, diarrhoea, dizziness, tiredness, numbness or tingling in the fingers or toes, face or mouth, changes in sensation of taste or smell, ringing or buzzing in the ears, loss of appetite, loss of weight, excessive thirst, mood change such as depression, pain at the injection site, flushing, skin rash, yellowing of the skin, need to urinated more often than usual, sudden severe back pain, which may be caused by kidney stones, bruising or bleeding more easily than normal, nosebleeds, signs of frequent or worrying infections, breathlessness, blood in urine, black tar like stools, confusion, lack of co-ordination, unsteadiness when walking, sensitivity to sunlight.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

BRAND INFORMATION

Brand name

Glaumox Powder for Injection

Active ingredient

Acetazolamide

Schedule

S4

 

1 Name of Medicine

Acetazolamide sodium.

2 Qualitative and Quantitative Composition

Each vial contains acetazolamide sodium, equivalent to 500 mg acetazolamide.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Glaumox is sterile lyophilised powder of acetazolamide sodium in a rubber capped vial. The sterile lyophilised powder is white to faintly yellowish white, crystalline, and odourless. The contents of the vial require reconstitution with water for injections for intravenous administration. The final solution is adjusted to pH 9.6 prior to lyophilisation.

4 Clinical Particulars

4.9 Overdose

No specific antidote is known. Treatment should be symptomatic and supportive, with correction of electrolyte and fluid balance. Electrolyte imbalance, development of an acidotic state, and central nervous effects might be expected to occur.
Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. No data available.
Carcinogenicity. No data available.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

The active ingredient of Glaumox is the acetazolamide sodium, or the sodium salt of N-(5-sulphamoyl-1,3,4-thiadiazol-2-yl) acetamide. Acetazolamide has a molecular weight of 222.25 (C4H6N4O3S2).
Acetazolamide sodium is a white or almost white crystalline powder, soluble in water.
Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSACETAZ.gif CAS number. The CAS for acetazolamide is 59-66-5.
The CAS for acetazolamide sodium is 1424-27-7.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/GLAUMOST.gif